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Abstract: Ion channels are complex transmembrane proteins that orchestrate the electrical signals necessary for normal 
function of excitable tissues, including the central nervous system, peripheral nerve, and both skeletal and cardiac muscle. 
Progress in molecular biology has allowed cloning and expression of genes that encode channel proteins, while compara-
ble advances in biophysics, including patch-clamp electrophysiology and related techniques, have made the functional  
assessment of expressed proteins at the level of single channel molecules possible. The role of ion channel defects in the 
pathogenesis of numerous disorders has become increasingly apparent over the last two decades. Neurological channelo-
pathies are frequently genetically determined but may also be acquired through autoimmune mechanisms. All of these 
autoimmune conditions can arise as paraneoplastic syndromes or independent from malignancies. The pathogenicity   
of autoantibodies to ion channels has been demonstrated in most of these conditions, and patients may respond well to  
immunotherapies that reduce the levels of the pathogenic autoantibodies. Autoimmune channelopathies may have a good 
prognosis, especially if diagnosed and treated early, and if they are non-paraneoplastic. This review focuses on clinical, 
pathophysiologic and therapeutic aspects of autoimmune ion channel disorders of the nervous system. 
Keywords: Ion channels, autoimmunity, voltage-gated calcium channels, voltage gated potassium channels, glutamate   
receptors, limbic encephalitis, Morvan’s syndrome, Lambert-Eaton myasthenic syndrome, neuromyotonia.  
1. INTRODUCTION 
  An emerging group of neurological disorders is associ-
ated with autoantibodies acting on ligand-gated ion channels 
(receptors) or on voltage-gated ion channels. These disorders 
can be divided into those in which the antibodies are markers 
for an inflammatory process targeting neurons but them-
selves likely not pathogenic (including anti-Hu and anti-Yo 
antibodies) [1, 2], and those in which the antibodies are di-
rectly pathogenic. This distinction is important since in the 
former the usefulness of immunotherapies is limited [3, 4], 
whereas the latter group of diseases typically responds better 
to treatment [5, 6]. In the first category the neurological dis-
order is thought to be caused by a T cell mediated attack on 
the neurons expressing the antigen, and the associated in-
flammation that this produces. The autoantibodies indicate 
that the patient has a tumor, but they are not usually directly 
pathogenic as the antigenic target is often intracellular. In the 
second category, to which autoimmune channelopathies be-
long, there is strong evidence that antibodies are directly 
pathogenic by reducing the expression and function of ion 
channels at the cell membrane. Their pathogenicity has been 
shown by passive transfer of purified IgG to mice [7], and by 
application to neuronal cell line cultures or transfected cells 
in vitro [8-10]. These autoimmune channelopathies can be 
diagnosed by standard laboratory tests and usually respond 
to immunotherapies that reduce the levels of the pathogenic 
autoantibodies [11]. 
  Autoimmune channelopathies can occur with or without 
cancer [12]. Paraneoplastic conditions are defined as those in  
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which the neurological disease is secondary to the presence 
of a tumor, but is not directly caused by the tumor itself. 
They result from the immune response that is generated 
against the tumor, which can usually be shown to express the 
neuronal antigen; the resulting T cells and autoantibodies 
cross-react with neuronal tissue [13]. Phenotypically, para-
neoplastic cases may not differ from non-paraneoplastic 
ones, although in some entities subtle clinical differences are 
being recognized. Certain channelopathies are associated 
with a higher risk of a paraneoplastic cause compared to   
others. 
2. DISORDERS ASSOCIATED WITH AUTOIMMU-
NITY TO VOLTAGE GATED CALCIUM CHANNELS 
(VGCC) 
2.1. Lambert Eaton Myasthenic Syndrome (LEMS) 
  Lambert-Eaton myasthenic syndrome (LEMS) [14] is a 
prototype paraneoplastic neurological syndrome: up to 60% 
of cases are associated with small cell lung cancer (SCLC) 
and rarely with other tumors [15]. Paraneoplastic LEMS may 
coexist with paraneoplastic encephalomyelitis, cerebellar 
degeneration (below), and sensory neuronopathy, especially 
in cases with SCLC [16]. Non-paraneoplastic cases tend to 
have a slower symptom progression and associate with other 
autoimmune conditions [15]. LEMS usually precedes tumor 
diagnosis by several months to years, presenting with pro-
gressive proximal weakness, affecting the legs more than the 
arms. There is less fatigability than in myasthenia gravis, but 
often muscle stiffness or pain after exertion. LEMS also dif-
fers from myasthenia in that it affects trunk and limb mus-
cles rather than bulbar ones. Respiratory and craniobulbar 
involvement is uncommon in LEMS and is generally mild 
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plegia should raise suspicion for superimposed encephalitis 
[16]. Autonomic dysfunction is prominent with dry mouth, 
dry eyes, impotence, orthostatic hypotension, and hyperhidrosis. 
Neurological examination shows proximal weakness and 
waddling gait, with characteristic improvement in muscle 
power after brief maximal voluntary muscle activity.   
Reflexes are diminished but may improve after forceful   
exercise of the corresponding muscles. 
  LEMS is a presynaptic disorder of neuromuscular trans-
mission. The autoimmune process results in depletion of 
VGCC and reduced calcium influx into the nerve terminal, 
leading to impaired quantal release of acetylcholine at the 
neuromuscular junction (NMJ). Acetylcholine release in-
creases with high frequency nerve stimulation or by raising 
extracellular calcium [17, 18]. Freeze-fracture studies in 
LEMS showed that the active zone particles on the presynap-
tic membrane, generally considered to be the VGCC, were 
reduced in numbers and formed into small aggregates rather 
than into the normal double parallel arrays [19]. The disease 
including the electrophysiological features could be pas-
sively transferred to mice by daily injection of IgG for three 
or more days [20]. These observations along with the dem-
onstration that the majority of patients responded well to 
immunomodulatory clearly implicated VGCCs as a target 
antigen in LEMS [21]. 
  Nerve conduction studies in patients with LEMS typi-
cally show reduced compound muscle action potential 
(CMAP) amplitudes recorded from rested muscle, which 
increase by at least 100% or more after brief voluntary iso-
metric contraction [22]. A similar CMAP increment occurs 
with high-frequency repetitive stimulation of 20-50 Hz (Fig. 
1), that may be used when patients are unable to voluntarily 
exercise. The CMAP increment likely results from facilita-
tion of acetylcholine release mediated by calcium influx. In 
contrast, routine low-frequency stimulation (2 to 3 Hz) re-
sults in decremental motor response, as in myasthenia. Nee-
dle electromyography (EMG) shows variability in amplitude 
and configuration of the recruited motor unit potentials 
(MUP). When neuromuscular dysfunction is severe, MUP 
may appear myopathic due to complete block of transmis-
sion to individual muscle fibers within each motor unit [15]. 
Single fiber EMG shows very high jitter values and block-
ing, both of which decrease as the MUP firing frequency 
increases, in contrast to myasthenia. 
 
 
 
 
 
Fig. (1). Electrophysiologic findings in Lambert-Eaton myasthenic 
syndrome. Repetitive stimulation of the ulnar nerve (50 Hz, train of 
50 stimulations) and recording at the abductor digiti minimi muscle 
in a patient with LEMS shows a ~100% increase in the compound 
muscle action potential amplitude (from 2.09 mV at the beginning 
to 4.04 mV at the end of the stimulation), characteristic of presyn-
aptic neuromuscular junction dysfunction. 
  VGCC are a family of multimeric ion channels that par-
ticipate in the generation of action potentials in dendrites, 
initiation of neurotransmitter release, and a variety of intra-
cellular regulatory processes. Different subtypes associated 
with specific genes, designated L, N, P/Q, R, or T differ in 
their voltage dependence, inactivation rate, ionic selectivity, 
and pharmacology [23]. Each Ca
2+ channel is composed of 
several different subunits (1, 2/,  and ). The diversity 
of genes encoding 1 subunits produces Ca
2+ channels with 
different properties and cell-specific expression. The large 
1 subunit contains the voltage sensing and ion selectivity 
elements, forms the channel pore and determines its sensitiv-
ity to various neurotoxins allowing specific labeling of 
VGCC subtypes. Antibodies were first detected in 40%–50% 
of LEMS patients using 
125I-conotoxin GVIA (
125I-CgTx) 
from  Conus geographus [24] to label N-type VGCCs ex-
tracted in digitonin from human brain tissue, although these 
are not thought to be functionally effective [25]. Subse-
quently, using 
125I-conotoxin MVIIC (
125I-CmTx) from C. 
magus, antibodies to mammalian P/Q-type VGCCs were 
demonstrated in over 85% of LEMS patients [21, 26]. Ca
2+ 
influx through these channels is inhibited by incubation in 
IgG from LEMS patients [27]. The P/Q-type VGCC antibod-
ies are present in patients with or without SCLC and SCLC 
cells express functionally active VGCC on their surface. The 
immune response to the tumor presumably leads to antibod-
ies directed at these VGCCs which then cross-react with 
those at the NMJ to cause the neurological disease. 
  The most important aspect of LEMS management is the 
early identification and treatment of the underlying malig-
nancy, which may also improve the neuromuscular manifes-
tations. Several studies have searched for possible serologi-
cal markers that may distinguish between paraneoplastic and 
non-paraneoplastic LEMS. Studies using recombinant pro-
teins corresponding to the extracellular S5-S6 linker region 
of individual domains forming the 1 subunit of P/Q-type 
VGCC showed that an antibody response to domain IV is 
more common in LEMS without tumor than in paraneoplas-
tic LEMS. This may have implications for diagnostic workup 
in LEMS patients without previously established diagnosis 
of a tumor. Additionally this could point towards a differen-
tial autoimmune pathogenesis between paraneoplastic and 
non-paraneoplastic LEMS [28]. Another possible marker for 
paraneoplastic LEMS is the presence of SOX1 antibodies: in 
a large series they were present in 64% of patients with 
LEMS and SCLC but in none with idiopathic LEMS [29]. 
However, routine measurement of VGCC antibodies in pa-
tients without clinical LEMS is unlikely to assist either in 
management of SCLC or in assessment of prognosis: 8% of 
SCLC patients may have raised serum VGCC antibodies but 
only 3% have LEMS on clinical and electrophysiological 
ground and VGCC antibody titers do not predict survival 
[30]. 
 Symptomatic therapy for LEMS includes 3,4-
diaminopyridine (3,4-DAP) and pyridostigmine. 3,4-DAP 
inhibits presynaptic voltage gated potassium channels 
(VGKC) and improves acetylcholine release. It has a narrow 
therapeutic window and continued monitoring during treat-
ment is needed. Common side effects with doses of 20-80mg 
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pitations and seizures [31]. Patients with aggressive disease 
may need immunosuppressive treatment, including corticos-
teroids, azathioprine, plasma exchange, and intravenous   
immunoglobulin (IVIg) [32]. Favourable response to rituximab 
has also been reported in a patient with LEMS and cerebellar 
syndrome associated with anti-VGCC antibodies [33].  
2.2. Cerebellar Ataxia Associated with VGCC Antibodies  
  Cerebellar dysfunction is one of the most common para-
neoplastic neurological disorders [13]. The underlying ma-
lignancy is usually SCLC, gynaecological and breast tu-
mours, and Hodgkin's lymphoma [4, 34]. Clinically, patients 
may present initially with viral-like illness, dizziness, nau-
sea, or vomiting, followed by gait unsteadiness. Neurological 
dysfunction progresses rapidly into ataxia, diplopia, 
dysarthria, and dysphagia [35]. MRI may be normal initially, 
but in later stages cerebellar atrophy becomes apparent. 
Pathologically, the hallmark of paraneoplastic cerebellar 
degeneration (PCD) is an extensive loss of Purkinje cells that 
might be associated with inflammatory infiltrates in the 
cerebellar cortex, deep cerebellar nuclei, and inferior olivary 
nuclei. Inflammation however is less prominent in PCD as-
sociated with anti-VGCC compared to the anti-Hu positive 
cases [34]. 
  Multiple autoantigens have been associated with PCD, 
including anti-Hu and anti-Yo antibodies. In a subset of pa-
tients without these antineuronal antibodies, raised VGCC 
antibodies are found. A small proportion of patients with 
paraneoplastic LEMS and associated SCLC also present with 
cerebellar ataxia. In a study of 39 patients with PCD, about 
40% had raised levels of VGCC antibodies in their serum 
and CSF, with evidence of intrathecal antibody production in 
some. Less than half of these patients with positive VGCC 
antibodies had LEMS, suggesting that VGCC antibodies 
should be looked for in patients with PCD, even if there are 
no symptoms of LEMS [36]. In a bigger series of 57 patients 
with presenting symptoms of PCD, 20% of cases with raised 
P/Q-type VGCC antibodies had no clinical evidence of 
LEMS [34]. Compared to patients with PCD and P/Q-type 
VGCC antibodies, patients with PCD and positive anti-Hu 
antibodies were more likely to be female, to have multifocal 
neurological involvement, to be severely disabled, and to die 
from neurological causes [34]. In general, SCLC patients 
with PCD have a worse outcome than patients without this 
complication of cancer. 
  As in the case of LEMS, there is increasing evidence that 
antibodies to VGCC play a pathogenic role in PCD. In con-
trast to the antibodies that target intracellular antigens, anti-
bodies against VGCC react with cell-surface epitopes; this 
and the fact that some patients have intrathecal synthesis of 
such antibodies has suggested a direct pathogenic role in the 
cerebellar dysfunction. The cerebellum, particularly the 
Purkinje and granule cells, are rich in P/Q and N-type of the 
VGCCs, which are also found at the NMJ and on the surface 
of SCLCs [37, 38]. Mice deficient in the gene encoding the 
P/Q-type VGCC develop ataxia and dystonia [39]. Autoanti-
bodies against the P/Q-type VGCC subtype from LEMS pa-
tients have been shown to decrease the calcium currents in 
cultured rat Purkinje and granule cells [37]. Furthermore, in 
autopsy material, P/Q-type VGCC were markedly reduced in 
the molecular layer of the cerebellum of LEMS patients with 
PCD compared to controls [40]. More recently, using a poly-
clonal peptide antibody against a major immunogenic region 
in P/Q-type VGCCs, Liao et al. [41] demonstrated that such 
antibody was sufficient to inhibit the function of neuronal 
and recombinant VGCCs, alter cerebellar synaptic transmis-
sion, and confer the phenotype of cerebellar ataxia. 
  Despite the fact that VGCC antibodies are considered 
pathogenic, PCD patients, in contrast to patients with LEMS 
do not respond favorably to immunotherapy. This is most 
likely due to the degree of irreversible neuronal destruction. 
Treatment of the malignancy is needed for PCD stabilisation 
or symptom improvement with or without immunotherapy. 
The use of corticosteroids, plasma exchange, IVIg, cyclo-
phosphamide, and tacrolimus had no significant impact   
on neurological outcome of patients whose tumours were 
successfully treated [13, 34]. 
3. DISORDERS ASSOCIATED WITH ANTIBODIES 
TO VOLTAGE-GATED POTASSIUM CHANNELS 
(VGKC)  
3.1. Acquired Neuromyotonia 
  There is a spectrum of disorders that arise from periph-
eral nerve hyperexcitability including neuromyotonia and 
cramp-fasciculation syndrome [42]. They can be inherited 
[43] or acquired on autoimmune basis. Acquired neuromyo-
tonia typically presents with muscle fasciculations and pain-
ful cramps, stiffness, myokymia, pseudomyotonia (delayed 
relaxation of contracted muscles) and hyperhydrosis. The 
limb and trunk muscles are most commonly affected. Up to 
20% of patients also have sensory symptoms such as paraes-
thesias, suggesting that sensory as well as motor nerves may 
be hyperexcitable [44]. 
  EMG in patients with neuromyotonia reveals spontane-
ous and repetitive (doublet, multiplet) discharges of single 
MUPs with variably high intraburst frequency. This neuro-
myotonic activity can always be blocked by local curare and 
variably by nerve block [45], indicating that it originates in 
the motor nerve rather than in the muscle itself. There is evi-
dence that the most distal portion of the nerve close to the 
NMJ is where hyperexcitability usually develops [46, 47]. 
Cramp-fasciculation syndrome is probably a milder version 
of the same condition, without neuromyotonic discharges in 
the EMG [42]. 
  Neuromyotonia can be associated with other autoimmune 
diseases including myasthenia, rheumatoid disease, systemic 
lupus erythematosus, diabetes mellitus, and others [45]. Ac-
quired neuromyotonia can also be a paraneoplastic condition, 
associated with thymoma in 10%–20% of cases, and more 
rarely with SCLC, Hodgkin’s lymphoma, and other malig-
nancies.  
 Immunoprecipitation  of 
125I-dendrotoxin-VGKCs ex-
tracted from human or rabbit cortex, demonstrated antibodies 
to VGKCs in about 40% of patients with NMT, although the 
antibody levels are not very high, and the test is less robust 
than that for acetylcholine receptor (AchR) or VGCCs [8]. 
Dendrotoxin only binds to the Kv1.1, 1.2 and 1.6 members 
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detecting VGKC antibodies has been increased by demon-
strating binding of patient sera to relevant neural tissues with 
high expression of VGKC (Fig. 2), as well as to different Kv 
subunits expressed in transfected Xenopus oocytes or in 
mammalian cells [48, 49]. 
 
 
 
 
 
 
 
Fig. (2). Binding of sera from patients with neuromyotonia 
(NMT) or Morvan’s Syndrome (MoS) to juxtaparanodal areas. 
Images of fixed mouse sciatic nerve teased fibers double stained 
with patient sera as indicated or a control serum (green) and a 
commercial antibody against Kv1.2, show colocalization of the 
MoS and NMT sera, but not of the control serum, with Kv1.2 ex-
pressed at axonal juxtaparanodes (arrows) as well as at the juxta-
incisures (open arrowheads). Scale bar: 10 μm. 
  To clarify the mechanism underlying NMT, passive 
transfer of IgG antibodies to mice resulted in resistance to 
curare [7], a modest increase in quantal content with pro-
longed action potentials in sensory nerves, and repetitive 
activity in dorsal root ganglion cultures [8]. These effects 
resemble the ones obtained with low concentrations (50 μM) 
of the potassium channel blockers 3,4-diaminopyridine or 4-
aminopyridine. NMT patients may improve with plasma 
exchange and other immunosuppressive treatments. Symp-
tomatic relief may be achieved with antiepileptic medica-
tions, which reduce nerve excitability by blocking sodium 
channels [50]. 
3.2. Morvan’s Syndrome 
  Morvan’s syndrome (MoS) or Morvan’s fibrillary chorea 
[51] describes rare patients with a combination of neuromyo-
tonia and CNS involvement. MoS can be associated with 
heavy metal intoxication (gold, mercury) or other toxins and 
also thymomas, suggesting an autoimmune etiology. Clini-
cally, the patients present with a combination of peripheral 
hyperexcitability with autonomic dysfunction such as hy-
perhidrosis and hypersalivation, as well as CNS disturbance, 
in the form of severe insomnia, mental confusion, visual 
hallucinations, delirium and prominent circadian hormonal 
disturbances [52-54]. 
  VGKC antibodies can be modestly or highly raised in 
most MoS patients. In general patients either improve spon-
taneously over time or respond more quickly to immunosup-
pressive treatments including steroids, azathioprine, IVIg, 
and particularly plasma exchange [52, 53, 55-57] or immu-
noadsorption [58]. 
3.3. Limbic Encephalitis 
  Limbic encephalitis (LE) has been recognized as an auto-
immune, non-paraneoplastic VGKC antibody-mediated dis-
ease affecting exclusively the CNS and most prominently the 
limbic areas [5, 59]. Patients develop acutely or subacutely, 
memory loss and confusion, leading over days or weeks to 
epileptic seizures (either temporal lobe or partial complex 
seizures). Cognitive impairment is profound with substantial 
retrograde and anterograde memory loss. MRI shows high 
signal in the hippocampal regions. In contrast to paraneo-
plastic LE, VGKC-antibody associated LE cases do not usu-
ally have a tumor, and can respond well, albeit sometimes 
over weeks rather than days, to immunotherapies [5, 6] with 
good recovery of memory and other CNS functions. REM 
sleep disturbances and hyponatraemia are common in both 
LE and MoS [60] and some patients develop hypothermia, 
hypersalivation, pain, and disorders of appetite [61]. In con-
trast to patients with MoS, LE patients lack clinical manifes-
tations of peripheral nerve hyperexcitability and most have 
normal peripheral electrophysiological studies as well [5]. 
  Patients with paraneoplastic LE usually have a SCLC and 
in around 50% anti-Hu antibodies are detectable. Other asso-
ciated onconeuronal antibodies in LE include Ma2, 
CV2/CRMP5 or amphiphysin [13]. Although most LE cases 
with VGKC antibodies are non-paraneoplastic, in up to 30% 
of cases there is also an underlying malignancy [62]. The 
neurological prognosis seems worse in VGKC antibody 
positive patients with paraneoplastic LE [63]. The presence 
of additional antibodies to anti-glial nuclear antibodies may 
predict paraneoplastic LE in patients with VGKC-antibodies 
[64]. Compared with other paraneoplastic or immune-
mediated LE, the CSF of patients with antibodies against 
VGKCs shows less pleocytosis and lower protein concentra-
tion and intrathecal synthesis of IgG [65, 66]. 
  Further paraneoplastic LE forms are associated with anti-
bodies to hippocampal neuropil, which are located on the 
membrane with usually good prognosis after tumor removal 
[65]. A high proportion of patients with non-paraneoplastic 
LE without neuropil or VGKC antibodies have antibodies to 
a novel cell-membrane antigen [67]. Given the emerging 
complexity of immunological associations in LE, it appears 
useful to classify patients into two main subgroups according 
to the location of the target antigens, either on the cell sur-
face, or intracellular. Overall, the former subgroup to which 
also cases with VGKC-antibodies belong tends to have a 
better prognosis, compared to the subgroup with intracellular 
target antigens [67]. Thus, about 80% of LE patients respond 
to corticosteroids, plasma exchange, or IVIg, especially if 
treated early, and if they have antibodies to cell surface anti-
gens, including VGKC [5, 6, 67]. 
3.4. VGKC Antibodies in Epilepsy and Hyperekplexia 
  In addition to the disorders described above, VGKC anti-
bodies were also found in 6% of patients with long-standing 
epilepsy [68], in one patient with hyperekplexia [69] and in 
some people without neurological symptoms. It is not sur-
prising that autoimmunity to VGKCs may cause epilepsy 
since genetic mutations affecting different VGKC are associ-
ated with seizure disorders [70, 71]. Furthermore, Kv1.1-
deficient mice develop spontaneous seizures with hippocam-
pal excitability [72]. Many of these VGKC-antibody-positive 
patients have drug resistant epilepsy and complex partial 
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antibodies were found in older patients with acute or suba-
cute onset of encephalopathic disorders. Immunomodulatory 
treatment resulted in reduction of seizures in some of these 
patients. Lower levels of VGKC antibodies were also found 
in cohorts of drug-resistant epilepsy patients, but immuno-
therapy was not instituted in these groups [68, 73]. Whether 
VGKC antibodies are pathogenic in these chronic epilepsy 
cases remains to be determined. 
3.5. VGKC and Autoimmune Mechanisms  
  VGKC are the most ubiquitous and diverse group of 
voltage-dependent ion channels found in the body [74]. 
Functional Kv channels are formed by homotetramers or 
heterotetramers of four alpha subunits, often associated with 
an auxiliary beta subunit [75]. The latter can modify the gat-
ing properties of the heteromultimeric channel complex [76]. 
This leads to a high degree of diversity in the neuronal K
+ 
channel population, probably serving specific physiological 
requirements of different locations [74, 77]. VGKC are ex-
pressed widely in the CNS and PNS but show a highly spe-
cific localization of individual Kv1 subunits in each area that 
may be functionally important. Kv1.1 and Kv1.2 are co-
expressed at the juxtaparanodal regions of the axons sur-
rounding the nodes of Ranvier [78, 79]. Here, they account 
for the Ki current that can be recorded by patch clamping of 
myelinated axons [80, 81] and contribute to the regulation of 
axonal membrane excitability, preventing repetitive dis-
charges.  
  In the CNS, a more complex distribution of numerous 
VGKC subunits in different regions has emerged [82], but 
the cerebellum and hippocampus have received most atten-
tion due to the genetic disorders associated with dysfunction 
of VGKC in these areas, especially epilepsy and episodic 
ataxia [71, 83]. Kv1.1-1.6 are highly expressed in different 
combinations in the cerebellar molecular and granule cell 
layers as well as at the basket cell terminals [84]; and in spe-
cific layers of the hippocampus that contain excitatory axon 
terminals, most prominently in the molecular layer of the 
dentate gyrus, in the CA3 mossy fiber zone and in the stra-
tum radiatum of CA1-3 [85-87]. VGKC play a major role in 
regulating the excitability of hippocampal neurons by modu-
lating neurotransmitter release, postsynaptic responses to 
excitatory inputs, neuronal spike properties, and firing fre-
quency [88]. 
  How autoantibodies impair VGKC function remains un-
clear. They appear to be heterogeneous and may bind to mul-
tiple Kv subunits [48, 49]. VGKC antibodies in NMT do not 
appear to block the function of Shaker-type K
+ channels di-
rectly, since short incubation (up to 2 hr) of cultured neu-
ronal cell lines with IgG from NMT patients has no effect. 
However, when applied for several hours, neuromyotonia 
antibodies reduce K
+ channel current amplitudes without 
changing gating kinetics [89, 90]. Thus, these antibodies 
appear, in a mechanism independent of added complement, 
to accelerate channel turnover and degradation of VGKC [9]. 
  The question why certain patients with VGKC antibodies 
present with a CNS disorder but others have only symptoms 
of peripheral nerve hyperexcitability, remains unresolved. 
Recent evidence suggests that sera from NMT, MoS LE   
patients may differentially affect the VGKC subtypes.   
Immunohistochemically, serum from VGKC-positive   
patients has been shown to produce distinct staining patterns 
on mammalian hippocampus similar to those observed by 
specific anti-Kv1 antibodies For example, serum from LE 
patients binds more prominently to Kv1.1-enriched areas of 
the hippocampus [49] (Fig. 3). It remains to be shown 
whether the distinct phenotypes of VGKC-associated disor-
ders are produced by differential specificity of antibodies for 
VGKC subtypes or associated proteins that are distinctly 
localized in the CNS and PNS. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Distinct binding of limbic encephalitis (LE) sera to 
hippocampal areas expressing VGKC. These are images of sec-
tions from fixed mouse hippocampus (CA3 area) immunostained 
with sera from NMT or LE patients as indicated (green) and com-
mercial antibodies against Kv1.2 (A-B) or Kv1.1 (C) (red). LE sera 
(but not the NMT serum) bind strongly to the mossy fiber layer 
(mf) where Kv1.1 but not Kv1.2 is prominently expressed. Kv1.2 is 
more prominent in the radiatum (rd) but LE sera do not bind there 
(or: stratum oriens; py: pyramidal layer).  
4. ALPHA3 GANGLIONIC ACETYLCHOLINE RE-
CEPTOR ANTIBODIES IN AUTOIMMUNE AUTO-
NOMIC NEUROPATHIES 
  Autoimmune aetiology has been recognized in some 
forms of peripheral autonomic disturbance. Autoimmune 
dysautonomias develop over days or weeks, persist for some 
months and then may partially resolve. Both the sympathetic 
and parasympathetic systems may be involved. Patients pre-
sent with orthostatic hypotension, impaired sweating, dry 
mouth and eyes, sexual dysfunction, urinary retention, im-
paired pupillary responses and defects in heart rate control. 
Gastrointestinal disturbances such as constipation or diarrhea 
may also occur. In a proportion of patients raised antibodies 
to the (3-type) acetylcholine receptor (AchR) containing the 
3 and 4 subunits, that is present in ganglionic synapses of 
the autonomic system, were detected [91]. Other cases may 
be associated with paraneoplastic antibodies such as anti-Hu 
and CRMP-5 [92]. Patients with orthostatic hypotension and 
prominent cholinergic dysautonomia are most likely to be 
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  Evidence for the pathogenicity of 3 AchR antibodies 
comes from studies showing correlation between titres and 
degree of autonomic impairment not only within an individ-
ual patient but also between patients. An animal model of the 
disease in the rabbit recapitulates the important clinical fea-
tures of the human disease [94]. Furthermore, a single injec-
tion of the rabbit or human antibodies into mice leads to 
autonomic dysfunction which may last for a few days and is 
followed by a compensatory overshoot in function as they 
recover [95]. Patients with chronic autoimmune autonomic 
neuropathy may respond to immunotherapies [96]. 
5. ANTIBODIES AGAINST GLUTAMATE AND GABA 
RECEPTORS 
5.1. Encephalitis associated with NMDA receptor anti-
bodies 
  The presence of antibodies against the N-methyl-D-
aspartate (NMDA) glutamate receptor was initially descibed 
in young women presenting with prodromal symptoms in-
cluding headache, fever, or a viral-like illness, and then de-
velop severe psychiatric symptoms, memory loss, seizures, 
decreased consciousness, accompanied by dyskinesias, hypo-
ventilation, or autonomic instability. The underlying malig-
nancy was ovarian teratoma [97]. Further studies in larger 
series of patients confirmed that this is a disease affecting 
predominantly young women in over 90% of cases with me-
dian age of 23 years (range 5-76 years) with the typical clini-
cal features as initially described [98]. In 60% of cases there 
was an underlying tumour, most commonly ovarian tera-
toma. Patients who received early tumour treatment and im-
munotherapy had better outcome. Immunotherapy often re-
sults in neurological improvement enabling tumour removal 
[99]. 
  Autoimmunity involving NMDA receptors has recently 
been identified also in children and a few men without a tu-
mour [100]. Some patients previously described as having 
acute diffuse lymphocytic meningoencephalitis, juvenile 
acute non-herpetic encephalitis, or acute juvenile female 
non-herpetic encephalitis had anti-NMDA receptor encepha-
litis [101]. Dyskinetic encephalitis lethargica in very young 
children has also been associated with anti-NMDA antibod-
ies [102]. Further studies in children showed that 40% of all 
encephalitis cases are associated with anti-NMDA antibod-
ies. Younger patients are less likely to have tumors, and 
clinically the phenotype resembles that of the adults, al-
though dysautonomia and hypoventilation are less prominent 
in children [103]. As with other channelopathies discussed 
above, antibodies to NMDA receptors are also detected in a 
proportion of patients with unexplained new-onset epilepsy. 
These cases present with prominent psychiatric symptoms 
and CSF pleocytosis, and they may develop hypoventilation 
[104]. 
  The main epitope targeted by the antibodies is in the ex-
tracellular N-terminal domain of the NR1 subunit. Patients' 
antibodies decreased the numbers of cell-surface NMDA 
receptors and NMDA-receptor clusters in postsynaptic den-
drites, an effect that could be reversed by antibody removal, 
strongly indicating that anti-NMDA antibodies are patho-
genic [98]. Anti-DNA antibodies, which cross-react with the 
NR2A and NR2B subunits of the NMDA receptor through a 
conserved pentapeptide sequence, were shown to cause hip-
pocampal cell death when injected into mouse brains, and 
animals immunised with the NR2A peptide developed high 
titres of specific NR2a antibodies which were able to gain 
access to the hippocampus. These animals developed mem-
ory loss [105]. The antibodies may act by stimulation of the 
NMDA receptor leading to glutamate-induced neurotoxicity. 
5.2. Encephalitis Associated with AMPA Receptor   
Antibodies  
  Another glutamate receptor has been recently added to 
the list of antigens involved in LE. In a series of 10 patients, 
Lai et al. [106] discovered antibodies to GluR1 and GluR2 
subunits of the alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) glutamate receptor. Me-
dian age was 60 (38-87) years. The majority were women 
and most of them had tumors of the lung, breast, or thymus. 
Most patients responded to immunotherapy or oncological 
therapy, but neurological relapses, without tumor recurrence, 
were frequent and influenced the long-term outcome. When 
applied to cultures of neurons, the patient’s antibodies sig-
nificantly decreased the number of GluR2-containing AMPA 
receptor clusters at synapses and these effects were reversed 
after antibody removal, confirming their pathogenicity [106]. 
  Autoimmunity to glutamate receptor 3 (GluR3), that also 
belongs to AMPA type, has long been associated with Ras-
mussen’s encephalitis, a severe form of intractable childhood 
epilepsy that is usually restricted to one hemisphere and 
leads to marked cognitive decline. The disease is associated 
with inflammatory and degenerative changes in the cerebral 
cortex and is extremely resistant to treatment. Immunization 
of rabbits with the GluR3 extracellular domain resulted in 
inflammation of the cortex and seizure activity [107]. How-
ever, the mechanism of action of these antibodies and their 
frequency and specificity in patients remains somewhat con-
troversial, while there is accumulating evidence that Ras-
mussen’s encephalitis is a T cell mediated disorder [108] and 
GluR3 antibodies may be secondary to the neuronal damage.  
5.3. Epilepsy Associated with Antibodies to GABA   
Receptor  
  More recently, antibodies to the GABA(B) receptor have 
been reported in a series of patients presenting with early or 
prominent seizures and other symptoms, MRI, and electro-
encephalography findings consistent with predominant lim-
bic dysfunction [109]. Immunoprecipitation and mass spec-
trometry showed that the autoantibodies recognize the B1 
subunit of the GABA(B) receptor, an inhibitory receptor that 
has been associated with seizures and memory dysfunction 
when disrupted. Half of the cases were found to have tu-
mours, mostly SCLC. Most patients responded to immuno-
therapy and cancer treatment. 
6. AQUAPORIN-4 ANTIBODIES IN NEUROMYELITIS 
OPTICA  
  Neuromyelitis optica (NMO) or Devic’s syndrome is an 
inflammatory and necrotizing disease clinically characterized 
by selective involvement of the optic nerves and spinal cord 
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known since the original description over hundred years ago. 
Bilateral optic nerves are severely affected and the myelitis 
is distinct, extending three or more spinal cord segments, and 
showing prominent cord cavitation and swelling. NMO pre-
dominantly affects young women and can be associated with 
other autoimmune diseases. Although NMO often follows a 
more aggressive clinical course than multiple sclerosis (MS) 
it may respond better to immunosuppressive therapy [111]. 
  There has been a long controversy as to whether NMO is 
a variant of MS or a distinct disease. In contrast to other de-
myelinating diseases, pathological examination in autopsy 
cases with NMO showed vasculocentric IgM, IgG and com-
plement component co-deposition [112]. Cellular infiltrates 
included predominantly neutrophils, eosinophils and B cells, 
with only a few T cells, suggesting humoral immunity as the 
major aetiology in NMO. Immunofluorescence demonstrated 
that NMO-IgG selectively binds to the pia mater, Virchow-
Robin spaces and the abluminal surface of cerebral mi-
crovessels [113], where it co-localises with aquaporin-4 
(AQP-4), a water channel protein, mainly expressed in astro-
glial foot processes. Subsequently, specific NMO-IgG bind-
ing was observed to cells expressing full length AQP-4, 
while it was absent in the brains of AQP-4-null mice [114]. 
  An immunohistopathological study in post-mortem brain 
and spinal cord tissue revealed that AQP-4 immunoreactivity 
was lost in 90% of acute and chronic NMO lesions in con-
trast to demyelinated MS plaques. Thus, astrocytic impair-
ment associated with the loss of AQP-4 and humoral immu-
nity may be important in the pathogenesis of NMO lesions 
[115]. Recent studies have demonstrated that human anti-
AQP-4 antibodies are not only important in the diagnosis of 
NMO but also pathogenic: they induced NMO-like lesions in 
animal models [116-118]. 
7. CONCLUSIONS 
  Autoimmune channelopathies have expanded rapidly in 
the last decades to include disorders of the peripheral, auto-
nomic and central nervous systems and an increasing number 
of target antigens. Although some of the neurological mani-
festations have been known for over a century, we are now 
beginning to understand the immunological associations and 
molecular mechanisms that lead to ion channel dysfunction 
in neural tissues. Parallel progress in the discovery of muta-
tions in ion channel genes causing phenotypically similar 
genetic disorders has stimulated further research into the 
common pathophysiological mechanisms. Acquired chan-
nelopathies are usually adult onset disorders some of which 
present relatively acutely or take a more subacute course. In 
most cases the underlying cause of the disease is not clear, 
but a tumor (especially SCLC or thymoma) must always be 
considered. The autoantibodies act mainly by increasing the 
turnover of the target antigens, depleting the neural tissue of 
their function. Some antibodies may bind to the agonist site 
or ion channel pore affecting the opening of the channel. 
Patients with autoimmune channelopathies may respond well 
to immunotherapies, and neurological damage may be mini-
mized if diagnosis and treatment are instituted early. There-
fore, it is important to recognize them clinically and under-
stand fully the mechanisms of these disorders, in order to 
improve therapeutic possibilities and outcome. 
ABBREVIATIONS 
LEMS  =  Lambert-Eaton myasthenic syndrome  
SCLC  =  Small cell lung cancer  
NMJ =  Neuromuscular  junction   
VGCC  =  Voltage gated calcium channels  
CMAP  =  Compound muscle action potential  
EMG =  Needle  electromyography   
MUP  =  Motor unit potential  
3,4-DAP =  3,4-diaminopyridine   
IVIg =  Intravenous  immunoglobulin 
PCD =  Paraneoplastic  cerebellar  degeneration 
VGKC  =  Voltage-gated potassium channels  
AchR  =  Acetylcholine receptor  
MoS =  Morvan’s  syndrome   
LE  =  Limbic encephalitis  
NMDA =  N-methyl-D-aspartate   
AMPA =  Alpha-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid  
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